Skip to Content
Merck
All Photos(1)

Key Documents

Safety Information

860638P

Avanti

C18 Glucosyl(β) Ceramide-d5

Avanti Research - A Croda Brand 860638P, powder

Synonym(s):

D-glucosyl-β-1,1′-N-stearoyl-D-erythro-sphingosine-d5

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C42H76D5NO8
CAS Number:
Molecular Weight:
733.13
UNSPSC Code:
12352100
NACRES:
NA.25

form

powder

packaging

pkg of 1 × 1 mg (860638P-1mg)

manufacturer/tradename

Avanti Research - A Croda Brand 860638P

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H][C@](/C=C/CCCCCCCCCCCC([2H])(C([2H])([2H])[2H])[2H])(O)[C@@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O

Application

C18 Glucosyl(β) Ceramide-d5 has been used as an internal standard for the quantification of glucosylceramide, in the extracts from mouse cerebellum by liquid chromatography-tandem mass spectrometry.

Packaging

5 mL Amber Glass Screw Cap Vial (860638P-1mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

No data available

Flash Point(C)

No data available


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

860638P-BULK:
860638P-VAR:
860638P-1MG:


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Victoria Schiffer et al.
PloS one, 15(1), e0227077-e0227077 (2020-01-14)
Gaucher disease is caused by a deficiency in glucocerebrosidase that can result in non-neuronal as well as neuronal symptoms. Common visceral symptoms are an increased organ size, specifically of the spleen, and glucosylceramide as well as glucosylsphingosine substrate accumulations as

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service